|Bid||160.17 x 1000|
|Ask||161.85 x 900|
|Day's range||158.60 - 161.60|
|52-week range||117.08 - 388.00|
|Beta (5Y monthly)||-0.08|
|PE ratio (TTM)||3.44|
|Earnings date||07 Nov 2022|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||02 Jun 2022|
|1y target est||240.07|
Vaxxinity missed out on Operation Warp Speed and the first round of COVID-19 vaccines, but CEO Mei Mei Hu is focused on the second generation and ongoing global needs.
After reporting worse than anticipated second-quarter earnings on Aug. 8, shares of BioNTech (NASDAQ: BNTX) are tumbling, deepening the stock's decline to 65% over the last 12 months. The culprit is the biotech's lackluster sales of Comirnaty, its coronavirus vaccine developed in conjunction with Pfizer.
This isn't shaping up to be a banner week for BioNTech (NASDAQ: BNTX). The bellwether coronavirus stock took it on the chin Monday and was being similarly battered by investors Tuesday because of post-earnings analyst price target cuts. Following second-quarter results that disappointed many investors, several analysts recalibrated their takes on BioNTech stock Tuesday.